Episode 740: GT Biopharma ($GTBP) CEO on Expanding Into Solid Tumors and Key 2026 Catalysts
Échec de l'ajout au panier.
Échec de l'ajout à la liste d'envies.
Échec de la suppression de la liste d’envies.
Échec du suivi du balado
Ne plus suivre le balado a échoué
Episode 740: GT Biopharma ($GTBP) CEO on Expanding Into Solid Tumors and Key 2026 Catalysts
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
Solid tumors represent one of the largest and most challenging areas in cancer treatment. In this interview, GT Biopharma (NASDAQ: GTBP) CEO Michael Breen explains why the company is expanding its platform into solid tumors and how its NK engager technology is designed to activate the body’s natural immune response.
Breen discusses the science behind GTB-5550, why B7H3 is a compelling target across many solid tumors, and how preclinical results support the company’s next steps. He also outlines key milestones from 2025 and what investors should watch as GT Biopharma moves toward clinical trials and data readouts in 2026.
Learn more about GT Biopharma: https://www.gtbiopharma.com/
Watch the full YouTube interview here: https://www.youtube.com/watch?v=I7-Vd8PO8L0
And follow us to stay updated: https://www.youtube.com/@GlobalOneMedia